DBV Technologies Misses With Viaskin Peanut Allergy Patch
The French firm's share price nearly halved on disappointing Phase III data for Viaskin while those of its rival, Aimmune, shot up, but all hope for the patch product is not yet lost.
You may also be interested in...
CBER’s novel biologic approvals in 2018 were few, long, and with a low level of innovation. But the center’s work to build regulatory framework for emerging technologies is setting the stage for a different story in 2019.
Proteostasis planned to raise cash this week, but scrapped the offering after an investor that shorted the stock published a scathing report. Also, Arena raised more than $350m in an offering after its positive Phase II etrasimod data, and venture capital flows to biopharma firms with big ideas.
Even better than expected efficacy and safety in the Phase III PALISADE trial puts Aimmune on track to file its BLA for peanut protein capsule AR101 by the end of 2018.